Madi Nada, Al-Nakib Widad, Pacsa Alexander
WHO Collaborative Centre for AIDS and Sexually Transmitted Disease for EMR, Virology Unit, Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait.
Adv Virol. 2011;2011:260561. doi: 10.1155/2011/260561. Epub 2011 Mar 24.
The resistance of cytomegalovirus (CMV) to ganciclovir or valganciclovir is a factor in therapeutic failure and disease progression. CMV strains resistant to ganciclovir or valganciclovir have been associated with specific mutations in the UL97 and UL54 genes. Sequencing of both CMV UL97 and UL54 genes was performed to detect the presence of CMV antiviral resistance in six patients who received ganciclovir (and/or valganciclovir) and had prolonged detectable CMV DNA in their blood during antiviral treatment. Sequencing results showed no specific mutations in either UL97 or UL54 gene of CMV and therefore the CMV strains in kidney transplant patients who received ganciclovir either prophylactically or therapeutically were from the wild type. Our results suggest that CMV management and immunosuppression protocols for kidney transplant patients followed in the Organ Transplant Centre, Kuwait, is very effective in reducing the opportunity of developing CMV antiviral resistance.
巨细胞病毒（CMV）对更昔洛韦或缬更昔洛韦的耐药性是治疗失败和疾病进展的一个因素。对更昔洛韦或缬更昔洛韦耐药的CMV毒株与UL97和UL54基因的特定突变有关。对6例接受更昔洛韦（和/或缬更昔洛韦）治疗且在抗病毒治疗期间血液中CMV DNA持续可检测到的患者进行了CMV UL97和UL54基因测序，以检测CMV抗病毒耐药性的存在。测序结果显示CMV的UL97或UL54基因均无特定突变，因此接受预防性或治疗性更昔洛韦的肾移植患者中的CMV毒株为野生型。我们的结果表明，科威特器官移植中心遵循的肾移植患者CMV管理和免疫抑制方案在减少发生CMV抗病毒耐药性的机会方面非常有效。
